SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Marcela TOMÍŠKOVÁ, Lenka JAKUBÍKOVÁ, Jana ŠPELDOVÁ, Bohdan KADLEC, Ondřej VENCLÍČEK, Monika BRATOVÁ, Andrea BENEJOVÁ and Zdeněk MERTA. Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno (Treatment with bevacizumab in combination with carboplatin and oral vinorelbine in patients with non-small cell lung cancer (NSCLC) at the Department of Pulmonary Diseases and TB, Masaryk University Faculty of Medicine and University Hospital, Brno). Studia pneumologica et phthiseologica. Praha: Trios s.r.o., 2019, vol. 79, No 3, p. 88-94. ISSN 1213-810X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Léčba bevacizumabem v kombinaci s karboplatinou a perorálním vinorelbinem u pacientu s nemalobunečnym karcinomem plic (NSCLC) na Klinice nemocí plicních a TBC, LF MU a FN Brno
Name (in English) Treatment with bevacizumab in combination with carboplatin and oral vinorelbine in patients with non-small cell lung cancer (NSCLC) at the Department of Pulmonary Diseases and TB, Masaryk University Faculty of Medicine and University Hospital, Brno
Authors SKŘIČKOVÁ, Jana (203 Czech Republic, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Marcela TOMÍŠKOVÁ (203 Czech Republic, belonging to the institution), Lenka JAKUBÍKOVÁ (203 Czech Republic, belonging to the institution), Jana ŠPELDOVÁ (203 Czech Republic, belonging to the institution), Bohdan KADLEC (203 Czech Republic, belonging to the institution), Ondřej VENCLÍČEK (203 Czech Republic, belonging to the institution), Monika BRATOVÁ (203 Czech Republic, guarantor, belonging to the institution), Andrea BENEJOVÁ (703 Slovakia, belonging to the institution) and Zdeněk MERTA (203 Czech Republic, belonging to the institution).
Edition Studia pneumologica et phthiseologica, Praha, Trios s.r.o. 2019, 1213-810X.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW Scopus
RIV identification code RIV/00216224:14110/19:00110660
Organization unit Faculty of Medicine
Keywords (in Czech) pokročilý nemalobuněčný karcinom plic; léčba; bevacizumab; orální vinorelbin
Keywords in English Advanced non-small cell lung cancer; Bevacizumab; Carboplatin; Oral vinorelbine; Treatment
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 1/4/2020 16:27.
Abstract
For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated.
Abstract (in English)
For patients with advanced NSCLC of non-squamous morphological diagnosis in whom neither epidermal growth factor receptor-activating mutation nor anaplastic lymphoma kinase gene rearrangement have been found, one possible treatment option is platinum-based chemotherapy in combination with bevacizumab. If after 4 to 6 cycles of this treatment, regression or disease stabilization is achieved, bevacizumab is further given as monotherapy (maintenance follow-up treatment). If bevacizumab treatment is indicated, the most common combination used in our center is bevacizumab with carboplatin and oral vinorelbine. The primary aim of the study was to evaluate the efficacy and safety of this approach. Treatment of 70 patients with advanced non-squamous NSCLC with the above combination was effective. So far, the median time to progression has been 5.1 months and the median survival 20.5 months. The therapy is very well tolerated.
PrintDisplayed: 27/7/2024 20:30